Indacaterol/glycopyrronium is cost-effective compared to salmeterol/fluticasone in COPD: FLAME-based modelling in a Swedish population

BACKGROUND: This study assessed the cost-effectiveness of indacaterol/glycopyrronium (IND/GLY) versus salmeterol/fluticasone (SFC) in chronic obstructive pulmonary disease (COPD) patients with moderate to very severe airflow limitation and ≥1 exacerbation in the preceding year. METHODS: A previously...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Respir Res
Main Authors: Bjermer, Leif, van Boven, Job F. M., Costa-Scharplatz, Madlaina, Keininger, Dorothy L., Gutzwiller, Florian S., Lisspers, Karin, Mahon, Ronan, Olsson, Petter, Roche, Nicolas
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2017
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5725803/
https://ncbi.nlm.nih.gov/pubmed/29228950
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12931-017-0688-5
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados